<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4972">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184662</url>
  </required_header>
  <id_info>
    <org_study_id>ACTIDIANE</org_study_id>
    <nct_id>NCT03184662</nct_id>
  </id_info>
  <brief_title>Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes</brief_title>
  <acronym>ACTIDIANE</acronym>
  <official_title>Randomized Trial to Assess the Efficacy of a High-intensity Physical Activity Program on Renal Function Decline in High Risk Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bichat Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Sud Francilien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Strasbourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HOSPITAL, CHARTRES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is a chronic condition whose prevalence is increasing globally. Kidney&#xD;
      disease is a key complication of diabetes and is among the most common cause of end-stage&#xD;
      renal disease, requiring renal replacement therapy.&#xD;
&#xD;
      It has been shown that the trajectory of renal function (estimated glomerular filtration rate&#xD;
      - eGFR) is of great prognostic value for renal and cardiovascular endpoints in diabetic&#xD;
      patients. However the clinical use of this prognostic marker is not associated to date with a&#xD;
      clear therapeutic intervention, effective in patients with type 2 diabetes identified with&#xD;
      this biomarker.&#xD;
&#xD;
      In France, type 2 diabetes patients have twice less physical activity than non-diabetic&#xD;
      persons. Recently, it has been published that physical activity was associated with an&#xD;
      improvement of renal risk in patients with type 2 diabetes, recruited from the LOOK-AHEAD&#xD;
      study. It was demonstrated that high-intensity physical activity (HIPA) can have several&#xD;
      additional advantages over moderate-intensity, on blood pressure improvement, and&#xD;
      cardiovascular risk profile modification. In addition, this procedure was shown to be safe in&#xD;
      patients with high cardiovascular risk.&#xD;
&#xD;
      We plan to perform a randomized intervention comparing a structured program of high-intensity&#xD;
      physical activity (HIPA) vs standard recommendations for physical activity on renal function&#xD;
      decline (primary outcome) and mortality, renal and cardiovascular endpoints, patients' safety&#xD;
      and quality of life (secondary outcomes). Study participants will be patients with&#xD;
      established type 2 diabetes and a high renal risk, identified by rapid renal function&#xD;
      decline, defined as a eGFR slope below -5ml/min per 1.73 m2/yr. The intervention is planned&#xD;
      to last for 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I- Visit organisation&#xD;
&#xD;
      V1 (screening) informed consent / examination / inclusion and non-inclusion criteria /&#xD;
      medical history M/F LUTS / EPICES score / ECG Serum creatinine determination&#xD;
&#xD;
      V2 (Randomization) examination / verification of participation criteria / randomization&#xD;
      Cystatin C collection / Biology Hypoglycemia notification / QAPPA / RPAQ / NAQA /&#xD;
      Questionnaires (EQ-5D3L, SF12, Rosenberg Self esteem) / Accelerometer (ancillary) /&#xD;
      Impedance-meter (ancillary) 6-minute step test / 10-meter walk test&#xD;
&#xD;
      V3 (1 month) examination / Hypoglycemia notification / QAPPA / RPAQ / Accelerometer&#xD;
      (ancillary)&#xD;
&#xD;
      V4 (3 months) examination / Hypoglycemia notification / QAPPA / RPAQ / Questionnaires&#xD;
      (EQ-5D3L, SF12, Rosenberg Self esteem) / Accelerometer (ancillary) 6-minute step test Biology&#xD;
&#xD;
      V5 (6 months) examination / Hypoglycemia notification / QAPPA / RPAQ /&#xD;
      Questionnaires(EQ-5D3L, SF12, Rosenberg Self esteem) / Accelerometer (ancillary) 6-minute&#xD;
      step test Cystatin C collection / Biology&#xD;
&#xD;
      V6 (12 months) examination / Hypoglycemia notification / QAPPA / RPAQ / NAQA / M/F LUTS /&#xD;
      Questionnaires(EQ-5D3L, SF12, Rosenberg Self esteem) / ECG /Accelerometer (ancillary) /&#xD;
      Impedance-meter (ancillary) Cystatin C collection / Biology 6-minute step test / 10-meter&#xD;
      walk test&#xD;
&#xD;
      V7 (18 months) examination / Hypoglycemia notification / QAPPA / RPAQ /&#xD;
      Questionnaires(EQ-5D3L, SF12, Rosenberg Self esteem) / Accelerometer (ancillary) Cystatin C&#xD;
      collection / Biology 6-minute step test&#xD;
&#xD;
      V8 (24 months) / premature discontinuation examination / Hypoglycemia notification / QAPPA /&#xD;
      RPAQ / NAQA / M/F LUTS / Questionnaires (EQ-5D3L, SF12, Rosenberg Self esteem) / ECG /&#xD;
      Accelerometer (ancillary) / Impedance-meter (ancillary) 6-minute step test / 10-meter walk&#xD;
      test Cystatin C collection / Biology&#xD;
&#xD;
      II- Recruitment criteria Inclusion&#xD;
&#xD;
        -  Age : 45 and higher&#xD;
&#xD;
        -  Female or male&#xD;
&#xD;
        -  Type 2 diabetes with diabetes typing according to widely-accepted clinical and&#xD;
           biological criteria [3].&#xD;
&#xD;
        -  Subject able to practice physical activity. This includes a normal exercise test with or&#xD;
           without anti-ischemic drugs, performed in the preceding 6 months or short before&#xD;
           randomization. A certificate of no contre-indication for PA is to be delivered prior to&#xD;
           randomization.&#xD;
&#xD;
        -  With at least 3 available creatinine measurements in the 6 to 24 preceding months&#xD;
           showing a rapid renal function decline defined as an eGFR slope below -5 ml/min/yr&#xD;
&#xD;
        -  Estimated GFR equal to or higher than 30 ml/min/1.73m², defined by the CKD-EPI formula,&#xD;
           at inclusion visit&#xD;
&#xD;
      Non inclusion&#xD;
&#xD;
        -  Age strictly lower than 45 years&#xD;
&#xD;
        -  Indication for cardiovascular rehabilitation (notably patient with ischemic heart&#xD;
           disease or coronary revascularisation)&#xD;
&#xD;
        -  Treatment with systemic NSAIDs or corticosteroids&#xD;
&#xD;
        -  Lower limb amputation (above trans-metacarpal)&#xD;
&#xD;
        -  Active proliferative retinopathy (risk of bleeding in case of effort)&#xD;
&#xD;
        -  Contra-indication for the participation to PA:&#xD;
&#xD;
             -  Severe non-operated valvulopathy&#xD;
&#xD;
             -  Uncontrolled hypertension &gt; 180/110 mmHg&#xD;
&#xD;
             -  Thrombus in the left ventricular cavity&#xD;
&#xD;
             -  Unstable coronaropathy, according to physician&#xD;
&#xD;
             -  NYHA stage IV heart failure&#xD;
&#xD;
        -  Any condition that would jeopardize patient's safety or would affect the conduct of the&#xD;
           study&#xD;
&#xD;
        -  Pregnant or breast-feeding women or women of child-bearing potential without effective&#xD;
           contraception during the study&#xD;
&#xD;
        -  Any situation associated with unreliable cystatin-C determinations, according to patient&#xD;
           medical history: HIV positivity, melanoma and thyroid dysfunction&#xD;
&#xD;
        -  Simultaneous participation to any interventional study able to interfere with the&#xD;
           current study endpoints&#xD;
&#xD;
        -  Patients not registered to the social security&#xD;
&#xD;
        -  Protected adults (under guardianship and trusteeship)&#xD;
&#xD;
        -  Subject unable to express their consent (due to intellectual/mental incapacity)&#xD;
&#xD;
      III- Intervention HIPA group Twice weekly physical activity session in a dedicated structure,&#xD;
      supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA,&#xD;
      allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every&#xD;
      3 months) adjustment of the intensity of the program.&#xD;
&#xD;
      Control group Counseling of physical activity according to recommendations from the working&#xD;
      group on Physical Activity of the SFD (French Language Diabetes Society) supported by&#xD;
      patient's oriented leaflet.&#xD;
&#xD;
      IV- Handling with the COVID-19 pandemics&#xD;
&#xD;
      The COVID-19 pandemics has modified the shape of the study with&#xD;
&#xD;
        -  difficulties to comply with the study plan, including recruitment pace. Visits can be&#xD;
           postponed if required but investigators are encouraged to follow the initial plan. The&#xD;
           time between randomization and V3 (1 month) and V4 (3 months) can sometimes be too short&#xD;
           and it is acceptable to perform this visit by phone or even to cancel it.&#xD;
&#xD;
        -  difficulties to comply with physical activity (PA) plan. As PA facilities have been&#xD;
           locked down in the pandemics context, the sports committee of the ACTIDIANE study has&#xD;
           agreed to move attendances to the gym to some remote PA sessions, via websession or if&#xD;
           not possible, via telephone coaching sessions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Function Decline</measure>
    <time_frame>2 years</time_frame>
    <description>Estimated glomerular filtration rate slope computed within 2 years, evaluated with the cystatin-derived CKD-EPI formula At least 3 available determinations of estimated glomerular filtration rate will be required to perform the calculation of the slope</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of ESRF</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of end-stage renal failure requiring renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a decrease in eGRF</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients with a decrease in eGRF greater than 40% of baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients who died during the study (all cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiovascular death as proposed by the ICD-10 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal death</measure>
    <time_frame>2 years</time_frame>
    <description>Renal death as defined as a situation where renal replacement therapy could be used but was not applied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>2 years</time_frame>
    <description>MACE : major adverse cardiovascular endpoints : first occuring among cardiovascular death, myocardial infarction and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe congestive heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>Severe congestive heart failure requiring hospitalization, adjudicated by a study outcome committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery disease</measure>
    <time_frame>2 years</time_frame>
    <description>Coronary artery disease : myocardial infarction and/or coronary artery revascularizaton</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EQ-5D3L</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life : assessed by using EQ-5D3L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Male/Female lower urinary tract symptoms (LUTS)</measure>
    <time_frame>2 years</time_frame>
    <description>Male/Female lower urinary tract symptoms : assessed by using M/F LUTS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the intervention</measure>
    <time_frame>2 years</time_frame>
    <description>including : adverse events, foot ulceration requiring medical advise, musculoskeletal disorders, hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life SF12</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life : assessed by using SF12 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of HIPA performed by e-coaching in the context of COVID infection</measure>
    <time_frame>2 years</time_frame>
    <description>AE and SAE will be carefully reviewed to assess if the HIPA sessions are safe as performed with e-coaching/ telephone-coaching during lock-down due to the COVID-19 pandemics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>HIPA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.&#xD;
The sessions will be preferably performed in sports gyms but if required can also be performed online with supervised coaches, trained for the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HIPA</intervention_name>
    <description>inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.&#xD;
First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months</description>
    <arm_group_label>HIPA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Counseling PA</intervention_name>
    <description>Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Rapid renal decline function (yearly loss of eGFR over -5ml/min/1.73 m2) in the 6 to&#xD;
             24 preceding months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lower limb amputation&#xD;
&#xD;
          -  Indication for rehabilitation program&#xD;
&#xD;
          -  Contra-indication for physical activity&#xD;
&#xD;
          -  Unstable angina, left atrial thrombus,&#xD;
&#xD;
          -  Unstable thyroid function&#xD;
&#xD;
          -  Corticosteroids treatment&#xD;
&#xD;
          -  Long-term NSAIDs&#xD;
&#xD;
          -  Simultaneous participation to any interventional study able to interfere with the&#xD;
             current study endpoints&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samy Hadjadj</last_name>
    <phone>00 33 253 48 27 01</phone>
    <email>samy.hadjadj@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Paquot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Besançon Hospital</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie Borot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Rigalleau, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yves REZNIK, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Chartres</name>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnaud Monier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand University Hospital</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Igor Tauveron, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHG Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfred Pernformis, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno Vergès</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Fontaine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69229</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Moulin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ariane Sultan, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philip Bohme, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Chevalier, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bichat University Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ronan Roussel, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Riboisière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-François Gautier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Agnès Hartemann, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre-Jean Saulnier, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathalie Jeandidier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Gourdy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de TOURS</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre-Henri Ducluzeau, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-intensity physical activity</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Renal function decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>sharing policy is under the responsibility of the scientific committee who will organise this point Any request can be posted to the PI in the meantime.</ipd_description>
    <ipd_time_frame>pending</ipd_time_frame>
    <ipd_access_criteria>pending</ipd_access_criteria>
    <ipd_url>https://actidiane.fr</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

